NCT00454571View on ClinicalTrials.gov

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Recurrent Prostate Cancer
Interventions
DRUG

pazopanib hydrochloride

Given PO

DRUG

leuprolide acetate

DRUG

goserelin acetate

Trial Locations (2)

53792

University of Wisconsin Hospital and Clinics, Madison

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00454571 - Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer | Biotech Hunter | Biotech Hunter